Search and Browse
Download
Enter Data
BDBM26366 4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-5-yl)-1-N-[3-(trifluoromethyl)phenyl]benzene-1,3-dicarboxamide::Aminopyrimidine amide, 10b
SMILES: Cc1ccc(cc1C(=O)Nc2cnc(nc2)Nc3ccc(cc3)N4CCN(CC4)C)C(=O)Nc5cccc(c5)C(F)(F)F
InChI Key: InChIKey=JZLAJYOZJKREKH-UHFFFAOYSA-N
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase Lck (Human) | BDBM26366![]() (4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl...) | GoogleScholar | UniChem | n/a | n/a | 0.5 | n/a | n/a | n/a | n/a | 7.5 | 22 | |
TBA | Citation and Details | ||||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Angiopoietin-1 receptor (Human) | BDBM26366![]() (4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl...) | GoogleScholar | UniChem | n/a | n/a | 123 | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details | ||||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Vascular endothelial growth factor receptor 2 (Human) | BDBM26366![]() (4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl...) | GoogleScholar | UniChem | n/a | n/a | 5 | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details | ||||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Mitogen-activated protein kinase 14 (Human) | BDBM26366![]() (4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl...) | GoogleScholar | UniChem | n/a | n/a | 10 | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details | ||||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| Tyrosine-protein kinase JAK3 (Human) | BDBM26366![]() (4-methyl-3-N-(2-{[4-(4-methylpiperazin-1-yl)phenyl...) | GoogleScholar | UniChem | n/a | n/a | 438 | n/a | n/a | n/a | n/a | n/a | n/a | |
TBA | Citation and Details | ||||||||||||
| More data for this Ligand-Target Pair | |||||||||||||